Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ribavirin ANDAs Await Decision By FDA; Par, Roche Expect Launch In August

Executive Summary

Par expects a final decision on the approvability of generic versions of ribavirin by Aug. 1

You may also be interested in...



Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

Ribavirin ANDAs Clear FDA; Schering Goes Generic Too

Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol

Par Generic Ribavirin Launch Expected In “Weeks”; ANDA Is “Approvable”

Par is forecasting a launch of generic Rebetol (ribavirin) in the first quarter following a Feb. 22 FDA "approvable" letter

Related Content

UsernamePublicRestriction

Register

PS042212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel